SI, sucrase-isomaltase, 6476

N. diseases: 117; N. variants: 15
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0028754
Disease: Obesity
Obesity
0.080 AlteredExpression disease BEFREE This study aimed at evaluating and comparing the chemical profile obtained by HPLC-ESI-MS<sup>n</sup> analysis, the inhibitory activity of enzymes linked to obesity (α-amylase, α-glucosidase, and lipase) and the antioxidant properties (DPPH, ABTS, FRAP, and β-carotene bleaching tests) of ethanol extracts of bulbs (BE) and aerial parts (APE) from Allium commutatum Guss. 31722087 2020
CUI: C0028754
Disease: Obesity
Obesity
0.080 Biomarker disease BEFREE Human α-glucosidase is an enzyme involved in the catalytic cleavage of the glucoside bond and involved in numerous functionalities of the organism, as well as in the insurgence of diabetes mellitus 2 and obesity. 29421954 2019
CUI: C0028754
Disease: Obesity
Obesity
0.080 GeneticVariation disease BEFREE Gray, and <i>Salvia officinalis</i> L. decoctions were investigated for their health-benefit properties, in particular with respect to antioxidant activity and inhibitory ability towards key enzymes with impact in diabetes and obesity (α-glucosidase, α-amylase and pancreatic lipase). 30513773 2018
CUI: C0028754
Disease: Obesity
Obesity
0.080 Biomarker disease BEFREE α-Glucosidase plays an important role in carbohydrate metabolism and is therefore an attractive therapeutic target for the treatment of diabetes, obesity and other related complications. 30282319 2018
CUI: C0028754
Disease: Obesity
Obesity
0.080 Biomarker disease BEFREE Cratoxylum cochinchinense displayed significant inhibition against protein tyrosine phosphatase 1B (PTP1B) and α-glucosidase, both of which are key target enzymes to attenuate diabetes and obesity. 29306546 2018
CUI: C0028754
Disease: Obesity
Obesity
0.080 Biomarker disease BEFREE Accordingly, nutritional composition, the content of phytochemical antioxidants, and the inhibitory ability of key enzymes with impacts on obesity and diabetes (α-glucosidase and pancreatic lipase) or on arterial pressure (angiotensin-I converting enzyme), were evaluated. 30274353 2018
CUI: C0028754
Disease: Obesity
Obesity
0.080 Biomarker disease BEFREE Inhibitory potential against key enzymes involved in diabetes (α-glucosidase and α-amylase), obesity (pancreatic lipase), neurodegenerative diseases (cholinesterases), and hyperpigmentation (tyrosinase) was evaluated. 28040595 2017
CUI: C0028754
Disease: Obesity
Obesity
0.080 Biomarker disease BEFREE Protein tyrosine phosphatase 1B (PTP1B) and α-glucosidase are important targets to treat obesity and diabetes, due to their deep correlation with insulin and leptin signalling, and glucose regulation. 28933230 2017